Asset
ZEDENOLEUCEL
MARKER THERAPEUTICS INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04511130 | phase2 | terminated | 2020-10-14 | 2024-03-01 | Marker Therapeutics, Inc. | Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant |
FDA applications (0)
This company has no applications containing this asset.